Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New web app aims to give heart patients a voice in End-of-Life care

NCT ID NCT06090734

First seen Apr 29, 2026 · Last updated Jun 20, 2026 · Updated 9 times

Summary

This study tests a web-based platform called 'My Voice' that helps heart failure patients learn about their illness, decide on end-of-life care goals, and share those wishes with doctors and caregivers. About 244 patients in Singapore will use the tool to see if it increases advance care planning discussions. The goal is to make care planning easier and more patient-driven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Duke-NUS

    Singapore, Singapore, 169857, Singapore

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

My Voice web-based interactive platform

What this could lead to

If successful, this could provide a practical tool for heart failure patients to better communicate their end-of-life care wishes with doctors and family.

What could go wrong

This is an early-stage study with 244 participants, so results may not apply to all patients. The tool may not improve care discussions or reduce distress as hoped.

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.